(Q42689189)

4 November 2017

1 reference

title

Topotecan: a new topoisomerase I inhibiting antineoplastic agent (English)

1 reference

4 November 2017

R J Cersosimo

1

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

Annals of Pharmacotherapy

4 November 2017

published in

1 reference

4 November 2017

volume

32

1 reference

4 November 2017

issue

12

1 reference

4 November 2017

page(s)

1334-1343

1 reference

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.

4 November 2017

cites work

1 reference

Clinical pharmacokinetics of topotecan

21 January 2018

1 reference

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

21 January 2018

1 reference

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

21 January 2018

1 reference

Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer

21 January 2018

1 reference

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

21 January 2018

1 reference

21 January 2018

Cancer statistics, 1998.

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

21 January 2018

1 reference

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

21 January 2018

1 reference

Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma

21 January 2018

1 reference

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

21 January 2018

1 reference

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

21 January 2018

1 reference

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

21 January 2018

1 reference

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

21 January 2018

1 reference

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

21 January 2018

1 reference

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

21 January 2018

1 reference

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Phase II evaluation of topotecan for pediatric central nervous system tumors.

21 January 2018

1 reference

Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma

21 January 2018

1 reference

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study

21 January 2018

1 reference

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

21 January 2018

1 reference

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

21 January 2018

1 reference

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.18049

1 reference

4 November 2017

1 reference